Kercheville Advisors LLC Trims Position in Eli Lilly and Company (NYSE:LLY)

Kercheville Advisors LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 3.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,213 shares of the company’s stock after selling 327 shares during the period. Eli Lilly and Company comprises approximately 2.5% of Kercheville Advisors LLC’s holdings, making the stock its 17th biggest holding. Kercheville Advisors LLC’s holdings in Eli Lilly and Company were worth $6,340,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. NovaPoint Capital LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $205,000. Vision Capital Management Inc. grew its holdings in Eli Lilly and Company by 23.6% in the fourth quarter. Vision Capital Management Inc. now owns 7,588 shares of the company’s stock valued at $5,858,000 after purchasing an additional 1,449 shares during the period. Schmidt P J Investment Management Inc. increased its position in Eli Lilly and Company by 1.8% during the fourth quarter. Schmidt P J Investment Management Inc. now owns 19,488 shares of the company’s stock worth $15,045,000 after purchasing an additional 345 shares during the last quarter. Onyx Bridge Wealth Group LLC raised its stake in Eli Lilly and Company by 14.1% during the fourth quarter. Onyx Bridge Wealth Group LLC now owns 1,027 shares of the company’s stock worth $792,000 after purchasing an additional 127 shares during the period. Finally, Tyche Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 52.6% in the 4th quarter. Tyche Wealth Partners LLC now owns 7,044 shares of the company’s stock valued at $5,438,000 after purchasing an additional 2,427 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.9 %

NYSE:LLY opened at $878.09 on Friday. The stock has a market cap of $833.59 billion, a price-to-earnings ratio of 94.93, a price-to-earnings-growth ratio of 1.72 and a beta of 0.42. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The business’s 50-day simple moving average is $788.21 and its 200 day simple moving average is $843.47.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.85 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.68%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Truist Financial upped their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Wells Fargo & Company reduced their price objective on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Barclays dropped their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.